FY2025 EPS Forecast for Solid Biosciences Reduced by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB) – HC Wainwright dropped their FY2025 EPS estimates for shares of Solid Biosciences in a report released on Wednesday, November 5th. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($1.98) for the year, down from their previous forecast of ($1.87). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q4 2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.12) EPS and FY2027 earnings at ($1.76) EPS.

Several other brokerages have also recently issued reports on SLDB. JPMorgan Chase & Co. decreased their price objective on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating for the company in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a report on Wednesday, October 8th. Cantor Fitzgerald set a $16.00 price target on shares of Solid Biosciences and gave the stock an “overweight” rating in a research note on Monday, July 21st. Wedbush dropped their price objective on shares of Solid Biosciences from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 13th. Finally, Barclays set a $9.00 price objective on shares of Solid Biosciences and gave the company an “overweight” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.70.

Solid Biosciences Price Performance

SLDB opened at $4.06 on Friday. The business has a fifty day moving average price of $5.56 and a 200 day moving average price of $5.05. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $7.37. The stock has a market capitalization of $316.31 million, a price-to-earnings ratio of -1.63 and a beta of 2.75.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06).

Institutional Investors Weigh In On Solid Biosciences

Hedge funds have recently made changes to their positions in the business. CWM LLC increased its position in Solid Biosciences by 15,188.5% in the 1st quarter. CWM LLC now owns 7,950 shares of the company’s stock valued at $29,000 after acquiring an additional 7,898 shares during the period. Legal & General Group Plc grew its stake in shares of Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after purchasing an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Solid Biosciences by 205.5% in the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares during the period. Ground Swell Capital LLC purchased a new stake in shares of Solid Biosciences during the first quarter worth approximately $42,000. Finally, Pallas Capital Advisors LLC purchased a new stake in shares of Solid Biosciences during the second quarter worth approximately $54,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.